Atigliflozin
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 647834-15-9
- 화학식: C18H22O7S
- 분자량:382.43
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
hSGLT2 10 nM (IC50) |
hSGLT1 8.2 μM (IC50) |
AVE2268 (10-100 mg/kg, p.o.) dose-dependently decreases blood glucose excursions after glucose (i.p. or p.o.) administration in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 647834-15-9
-
분자량 382.43
-
화학식 C18H22O7S
-
SMILES
O[C@H]1[C@H](OC2=C(CC3=CC=C(OC)C=C3)SC=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
-
Synonyms
AVE-2268
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. [Content Brief]
[2]. Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)